Spark Therapeutics (ONCE) Downgraded by Chardan Capital

Chardan Capital cut shares of Spark Therapeutics (NASDAQ:ONCE) from a buy rating to a neutral rating in a research report report published on Monday, Marketbeat reports. Chardan Capital currently has $85.00 price target on the biotechnology company’s stock, up from their previous price target of $80.00.

A number of other equities analysts have also weighed in on ONCE. BMO Capital Markets set a $67.00 target price on Spark Therapeutics and gave the stock a buy rating in a research note on Tuesday, January 2nd. Cantor Fitzgerald set a $105.00 target price on Spark Therapeutics and gave the stock a buy rating in a research note on Wednesday, January 3rd. SunTrust Banks increased their target price on Spark Therapeutics to $113.00 and gave the stock a buy rating in a research note on Thursday, January 4th. Raymond James set a $66.00 target price on Spark Therapeutics and gave the stock a buy rating in a research note on Wednesday, January 3rd. Finally, Wedbush lowered Spark Therapeutics from a neutral rating to an underperform rating and lowered their target price for the stock from $50.00 to $35.00 in a research note on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and sixteen have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $71.89.

Shares of NASDAQ ONCE opened at $73.83 on Monday. The company has a market cap of $2,905.41, a PE ratio of -9.68 and a beta of 2.56. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($1.73). The company had revenue of $7.41 million for the quarter, compared to analyst estimates of $9.53 million. Spark Therapeutics had a negative return on equity of 59.38% and a negative net margin of 2,100.80%. research analysts expect that Spark Therapeutics will post -3.33 EPS for the current year.

In other Spark Therapeutics news, COO John Furey sold 13,277 shares of the firm’s stock in a transaction on Wednesday, April 18th. The stock was sold at an average price of $82.52, for a total transaction of $1,095,618.04. Following the transaction, the chief operating officer now owns 2,277 shares in the company, valued at approximately $187,898.04. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 40,000 shares of company stock worth $3,200,466. Corporate insiders own 7.30% of the company’s stock.

Several hedge funds have recently modified their holdings of the business. Aperio Group LLC boosted its holdings in shares of Spark Therapeutics by 29.2% in the 4th quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 898 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Spark Therapeutics by 5.0% in the 4th quarter. The Manufacturers Life Insurance Company now owns 21,428 shares of the biotechnology company’s stock valued at $1,102,000 after purchasing an additional 1,013 shares in the last quarter. Great West Life Assurance Co. Can boosted its holdings in shares of Spark Therapeutics by 47.3% in the 3rd quarter. Great West Life Assurance Co. Can now owns 3,939 shares of the biotechnology company’s stock valued at $351,000 after purchasing an additional 1,264 shares in the last quarter. Glenmede Trust Co. NA boosted its holdings in shares of Spark Therapeutics by 15.5% in the 4th quarter. Glenmede Trust Co. NA now owns 10,850 shares of the biotechnology company’s stock valued at $557,000 after purchasing an additional 1,456 shares in the last quarter. Finally, California State Teachers Retirement System boosted its holdings in shares of Spark Therapeutics by 3.8% in the 3rd quarter. California State Teachers Retirement System now owns 42,716 shares of the biotechnology company’s stock valued at $3,809,000 after purchasing an additional 1,570 shares in the last quarter.

WARNING: “Spark Therapeutics (ONCE) Downgraded by Chardan Capital” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2018/04/26/spark-therapeutics-once-downgraded-by-chardan-capital.html.

About Spark Therapeutics

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply